Abstract
Background:Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1 and 2, approved for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults.Objectives:Here we update...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have